We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-23.09%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$87.1M
AUM Growth
-$26.1M
Cap. Flow
+$2.08M
Cap. Flow %
2.38%
Top 10 Hldgs %
66.86%
Holding
37
New
6
Increased
12
Reduced
6
Closed
11

Top Buys

Rank Stock Value
1
FMI
Foundation Medicine, Inc.
FMI
+$3.54M
2
EDIT icon
Editas Medicine
EDIT
+$2.25M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$2.2M
4
KITE
Kite Pharma, Inc.
KITE
+$2.18M
5
EPZM
Epizyme, Inc
EPZM
+$2.15M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$5.76M
2
GHDX
Genomic Health, Inc.
GHDX
+$3.02M
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$2.41M
4
NVTA
Invitae Corporation
NVTA
+$2.05M
5
BPMC
Blueprint Medicines
BPMC
+$1.58M

Sector Composition

Rank Sector Weight
1 Healthcare 85.32%
2 Industrials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OXFD
26
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$198K 0.23%
20,000
-55,000
-73% -$564K
AGIO icon
27
CALL
Agios Pharmaceuticals
AGIO
$1.82B
– –
-5,000
Closed -$325K
ATRA icon
28
Atara Biotherapeutics
ATRA
$77M
– –
-1,000
Closed -$660K
BLUE
29
CALL
DELISTED
bluebird bio
BLUE
– –
-1,544
Closed -$1.28M
CRDF icon
30
Cardiff Oncology
CRDF
$72.7M
– –
-972
Closed -$378K
ILMN icon
31
CALL
Illumina
ILMN
$30B
– –
-20,560
Closed -$3.84M
ILMN icon
32
Illumina
ILMN
$30B
– –
-30,840
Closed -$5.76M
OSUR icon
33
OraSure Technologies
OSUR
$286M
– –
-170,000
Closed -$1.09M
NVTA
34
DELISTED
Invitae Corporation
NVTA
– –
-250,000
Closed -$2.05M
GNMK
35
DELISTED
GenMark Diagnostics, Inc
GNMK
– –
-310,000
Closed -$2.41M
FMI
36
CALL
DELISTED
Foundation Medicine, Inc.
FMI
– –
-15,000
Closed -$316K
JUNO
37
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-17,500
Closed -$769K
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q1 2016 Portfolio in Review

As of Q1 2016, Casdin Capital held 37 positions worth $87.1M, down 23% from $113M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Casdin Capital's Q1 2016 filing shows 6 new, 12 increased, 6 reduced and 11 closed positions. Its largest new stake was Editas Medicine: 85,470 shares worth $2.95M. The largest sale was Illumina, an estimated $5.76M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 77% a quarter earlier, followed by Industrials.

  • Casdin Capital's largest Q1 2016 buy was Editas Medicine: 85,470 shares worth $2.95M.
  • Casdin Capital added most to Foundation Medicine, Inc. in Q1 2016, an estimated $3.54M increase.
  • Casdin Capital's biggest Q1 2016 reduction was Genomic Health, Inc., cutting an estimated $3.02M.
  • Casdin Capital fully exited Illumina in Q1 2016, selling an estimated $5.76M.
  • Casdin Capital's ten largest holdings make up 67% of its $87.1M portfolio in Q1 2016.
  • Casdin Capital opened 6 new positions and closed 11 in Q1 2016.
  • Casdin Capital's portfolio value fell 23% quarter-over-quarter to $87.1M.

Based on Casdin Capital's 13F filing for Q1 2016, filed 9 May 2016.